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Abstract
Comprehensive stroke care is an interdisciplinary challenge. Close collaboration of cardiologists and stroke physicians is
critical to ensure optimum utilisation of short- and long-term care and preventive measures in patients with stroke. Risk
factor management is an important strategy that requires cardiologic involvement for primary and secondary stroke
prevention. Treatment of stroke generally is led by stroke physicians, yet cardiologists need to be integrated care
providers in stroke units to address all cardiovascular aspects of acute stroke care, including arrhythmia management,
blood pressure control, elevated levels of cardiac troponins, valvular disease/endocarditis, and the general management
of cardiovascular comorbidities. Despite substantial progress in stroke research and clinical care has been achieved,
relevant gaps in clinical evidence remain and cause uncertainties in best practice for treatment and prevention of stroke.
The Cardiovascular Round Table of the European Society of Cardiology together with the European Society of
Cardiology Council on Stroke in cooperation with the European Stroke Organisation and partners from related scientific
societies, regulatory authorities and industry conveyed a two-day workshop to discuss current and emerging concepts
and apparent gaps in stroke care, including risk factor management, acute diagnostics, treatments and complications, and
operational/logistic issues for health care systems and integrated networks. Joint initiatives of cardiologists and stroke
physicians are needed in research and clinical care to target unresolved interdisciplinary problems and to promote the
best possible outcomes for patients with stroke.
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Introduction
Stroke is a major burden on patients, caregivers, health-
care systems and society. At the beginning of this century,
approximately 1.1 million inhabitants of Europe suffered
a stroke each year. These numbers are expected to
increase by 2025 to 1.5 million owing to the ageing popu-
lation and persistence of risk factors. Stroke is a major
cause of mortality and a leading cause of physical disabil-
ity, hospitalisation, dementia and depression.1
Approximately one-third of patients die within a year
due to the index stroke, one-third survive with major
physical impairment, and one-third have minor impair-
ment but still often face limitations in work and daily life
activities. A wide variation of stroke mortality is observed
across European countries with a north-south and an
east-west gradient ranging from about 300/100,000 inhab-
itants in eastern European countries to around 60/
100,000 in northern and central Europe.2 Thus, both
the clinical and socioeconomic burden of stroke is high.
Stroke has multiple risk factors, diverse pathophysi-
ology (e.g. ischaemic (approximately 85%), haemor-
rhagic (approximately 15%)) and various aetiology
subtypes (e.g. atherosclerotic, cardioembolic, small
vessel disease, rare causes and unknown causes).3 This
heterogeneity in risk factors, pathophysiology and aeti-
ology determines the complexity of optimal prevention
and treatment strategies, and underscores the challenge
of stroke as an acute syndrome.
The brain and the heart are intricately linked in the
context of stroke with the heart being both cause and
target of stroke pathophysiology and complications. In
state-of-the-art practice, stroke physicians direct the
care of patients with acute stroke, with cardiologist
expertise being essential for multiple aspects including
early causal diagnostic workup, monitoring and man-
agement of acute cardiovascular complications.
Management of risk factors such as atrial fibrillation
(AF), arterial hypertension, valvular and coronary
artery disease and long-term secondary prevention all
benefit from cardiologist involvement in integrated,
interdisciplinary stroke care models.4
To promote the interdisciplinary efforts of cardiolo-
gists for prevention and clinical treatment of stroke, the
European Society of Cardiology (ESC) formed the
Council on Stroke. The aim of the council is to improve
education, diminish inequalities in clinical standards
across Europe, and encourage research. The
Cardiovascular Roundtable (CRT), a strategic platform
of the ESC to advance health care strategies,5 together
with the ESC Council on Stroke convened a two-day
workshop inMarch 2018 to identify current and emerging
unmet needs and evidence gaps. Renowned experts from
multiple specialties involved in stroke care together with
European and US-American academic leaders, regulators
and experts from industry were invited by the ESC lead-
ership to join the discussion. This paper summarises the
targeted priorities and collaborative steps to address the
needs of patients at-risk for or already impacted by stroke
(Table 1). Comprehensive stroke care and stroke preven-
tion involves multiple other disciplines (e.g. physiother-
apy, psychological, nutritional and social care) besides
neurologists, neuro-radiologists, cardiologists and vascu-
lar surgeons, and for long-term treatment also involves
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general practitioners and geriatricians, but these topics are
outside the scope of this article and not discussed herein.
Causality, prevention, and risk factor
management
Risk factor management for primary prevention
Primary prevention of stroke involves both screening
for and treatment of major risk factors including hyper-
tension, AF, arteriosclerotic artery disease, elevated
blood cholesterol levels as well as lifestyle factors
such as smoking, alcohol, physical inactivity or obesity;
and other risk factors such as diabetes mellitus, health
related quality of life, or a family history of stroke or
AF.6 Poor control of these risk factors has been
reported in general populations,7 as well as in patients
with ischaemic stroke. Gender differences in stroke are
incompletely understood, low testosterone levels have
been observed with increased risk of AF and hence
ischaemic stroke in men but not in women.8 It is
acknowledged that implementation of primary
Table 1. Priorities for cardiovascular research in stroke.
Risk factor management for primary prevention
 Validate processes to improve implementation of, and adherence to, primary prevention strategies.
 Determine relative importance of risk factors in specific stroke subtypes.
 Blood pressure: identify optimal blood pressure targets for prevention of stroke overall, and by stroke subtype and accounting for
comorbidities.
 Cholesterol: identify target lipid levels relating to stroke subtypes for individualised therapy.
 AF: further define and validate the burden of AF (and other atrial arrhythmias)
– Refine stroke risk.
– Define needs, timing and specifics of anticoagulation therapy.
– Define thresholds for the impact of AF burden and how cardiac-implanted electronic devices can help physicians to prevent
stroke in at-risk patients.
– Identify and validate the role of atrial fibrosis and blood stasis in the pathophysiology of AF-related stroke and as potential
therapeutic targets.
 Validate wearable technology or mobile health applications for detection of AF and investigate whether arrhythmia detection by
these devices leads to a reduction in the risk of stroke.
 Examine the need and added contribution of integrating emerging risk factors in current risk scores.
 Development and validation of bleeding risk scores specifically in AF and in high-risk stroke populations.
 Investigate and validate a precision-medicine approach to antiplatelet therapy in patients with atherosclerotic cardiovascular
disease; targeting patients most likely to benefit and least likely to experience harm or non-response.
 Evaluate efficacy and safety of therapeutic alternatives for patients with AF, high ischaemic stroke risk, and contraindications for
long-term anticoagulation, e.g. left atrial appendage closure.
Risk factor management for secondary prevention
 Validate a precision-medicine approach to antithrombotic therapy for secondary prevention including dual and combination
therapy with NOACs according to individual risk profiles.
 Revision and adjustment to the ESUS concept vs intensified prolonged search for AF.
 Collaborative model of care; dedicated interdisciplinary clinics focused on implementation of secondary prevention strategies.
Acute diagnostics
 Innovations to shorten time between symptom onset and treatment (e.g. combined CT and angiography, mobile stroke unit,
angiography only, flat-detector CT).
Acute treatments
 Role of percutaneous thrombectomy in: posterior circulation, basilar artery occlusion; substantial disability (modified Rankin
score 2); large baseline infarcts; NIHSS score 10; longer duration of time since patient last known to be well.
 Evidentiary requirements for new endovascular devices.
 Need for concomitant intravenous thrombolysis and thrombectomy.
 Establishing mechanisms and validate treatment concepts for stroke-induced neurogenic stress cardiomyopathy.
Healthcare systems and integrated networks
 Improving patient access to stroke centres.
 Validate consistent incorporation of cardiology expertise in acute and subacute stroke care.
 Demonstration projects documenting improved patient outcomes, less disability, less socioeconomic burden associated with
timely delivery of evidence-based treatments.
 Establishing the benefits of long-term specialised post-stroke care including specialised nurses and cardio-neuro monitoring and
risk management.
AF: atrial fibrillation; CT: computed tomography; ESUS: Embolic Stroke of Unknown Source; NIHSS: National Institutes of Health Stroke Scale; NOAC:
novel anticoagulation.
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prevention strategies may be more difficult than initia-
tives for secondary prevention, owing to a broader
target population and less well-defined patient groups.
Almost any cardiac pathology may account for an
increase in the risk of stroke, yet stroke may often be
the first clinical event of a previously undetected cardiac
disease that requires further diagnostic and treatment
measures (Figure 1).
Blood pressure. Arterial blood pressure is the most
important risk factor for both ischaemic and haemor-
rhagic stroke, and lowering blood pressure reduces the
risk of stroke, irrespective of the pre-treatment blood
pressure level.9,10 Targets for blood pressure levels as
recommended by the guidelines of the European
Society of Cardiology/European Society of
Hypertension are 120–129mm Hg in most patients
<65 years of age and 130–139mm Hg for patients
65 years of age.11 Recent evidence, however, may
challenge such global blood pressure targets as the
risk associated with hypertension may depend on a
wider range of interrelated factors including not only
age but also type of stroke, comorbidities and cardio-
vascular risk profile.12 Further uncertainty exists on the
blood pressure variables that need most attention, i.e.
absolute blood pressure, pulse pressure, as well as iso-
lated systolic or diastolic blood pressure elevations or
diurnal trends.13 Owing to the log-linear relationship
between blood pressure and stroke incidence, the
choice of a specific blood pressure target to prevent a
stroke is not supported by strong evidence.
Despite the clear understanding that uncontrolled
hypertension is a strong risk factor for stroke, there is
still an unacceptably high prevalence of undetected
hypertension as well as of detected but not treated or
not effectively treated hypertension. Further research
and educational work is clearly needed to target this
modifiable risk factor.
Cholesterol. Cholesterol is a strong risk factor for ischae-
mic heart disease and myocardial infarction (MI). In
ischaemic stroke, however, the impact of cholesterol is
less clear as the association of high cholesterol and
mortality risk is much weaker and only seen at younger
ages (40–59 years). Lowering total cholesterol is asso-
ciated with a lower risk of ischaemic stroke but relates
to a marginally greater risk of haemorrhagic stroke in
some series.14 Again, this observation also varies by
• Myocardial infarction
• Myocarditis
• Endocarditis
• LV Aneurysm 
• Chronic heart failure 
• Valvular disease
• Valve replacement 
• Overt foramen ovale
• Congenital defects
• Atrial fibrillation
• Hypertension
• Atherosclerosis
• Contractile function 
• Neurogenic myocyte injury   
• Arrhythmias
• Inadequate BP regulation 
• Microvascular dysfunction  
• Cardiac / vascular re-embolism 
• Myocardial Infarction
• CHF exacerbation
Prevalent comorbidities and risk factors 
Primary and secondary prevention 
Acute stroke-induced cardiac complications
(cardiac troponins    ) 
Figure 1. The cardio-stroke interaction for prevention and treatment of stroke and related complications.
Cardiac diseases and injuries can be both cause and consequence of stroke. Cardiac pathologies may often remain undetected with the
stroke being the first clinical incident. Cardiovascular diagnostic work-up and monitoring of cardiovascular complications in acute and
subacute stroke require involvement of cardiologic expertise in the interdisciplinary team for state of the art stroke care. LV: left
ventricle; BP: blood pressure.
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age. These findings are consistent with the effects of
statin and proprotein convertase subtilisin kexin 9
(PCSK9) inhibitor therapy on lowering the risk of
ischaemic, but not haemorrhagic stroke. Genome-asso-
ciated studies further suggest specific patterns in risk
factors and pathophysiology depending on the subtype
of stroke. Accordingly, a weak association between
low-density lipoprotein cholesterol (LDL-C) and
ischaemic stroke has been observed for large artery ath-
erosclerosis strokes, but not for small artery occlusion
or cardioembolic stroke subtypes.15 Knowledge of the
primary pathophysiology of plaque load in an individ-
ual patient may enable more precise targeting of indi-
vidual risk factors and prevention strategies.16 The
optimum treatment regimen balancing efficacy on
stroke aetiology and accounting for patient specific sus-
ceptibility has yet to be determined.
Atherosclerotic cardiovascular disease. Patients with symp-
tomatic atherosclerosis, for example those with carotid
artery disease or a prior MI, are also at increased risk
for atherothrombotic stroke. This underscores that
pathophysiology and risk factors for atherosclerosis in
the coronary and cerebral vasculature are similar (e.g.
elevated cholesterol, smoking, lifestyle factors) albeit
substantial differences as to the strength of impact
may exist.17 Whilst intervention for symptomatic and
asymptomatic18 carotid stenosis is beneficial for long-
term stroke prevention, medical treatments, including
antiplatelet therapy in patients with atherosclerotic car-
diovascular disease, reduce the risk of stroke. In fact,
substantial evidence has been accumulated on the effi-
cacy of antiplatelet therapy to prevent repeated ischae-
mic events (see also below for secondary prevention).
Interventional concepts for carotid vascular disease (i.e.
endarterectomy vs carotic stenting) depend on meticu-
lous measures of quality control, high volume centres
and adequate patient selection, and are a matter of
ongoing studies.
Some evidence suggests that more intense therapy
(such as aspirin in combination with ticagrelor) is
more effective to reduce the risk of stroke than low
dose treatment with aspirin alone.19 More robust
evidence, however, on optimum dosing, intensity and
duration of antiplatelet therapy in patients with
atherosclerotic disease is warranted from ongoing
trials (ANDAMAN (ClinicalTrials.gov identifier:
NCT0252092), ADAPTABLE (ClinicalTrials.gov
identifier: NCT02697916)). Uncertainty exists particu-
larly in patients with low cardiovascular risk profile
as the potential benefit of antiplatelet therapy is less
pronounced and may be increasingly outweighed by
the risks of bleeding. Accordingly, recent trials have
further challenged the net benefit of aspirin in primary
prevention (ASPREE (ClinicalTrials.gov identifier:
NCT01038583), ASCEND (ClinicalTrials.gov identi-
fier: NCT00135226)). Notable, discrepant guideline
recommendations on the use of antiplatelet therapy in
patients with low cardiovascular risk are given in
Europe and the USA which underscore the need for
further evidence.
Atrial Fibtrillation (AF). AF is associated with an increased
risk for cardioembolic stroke, but the debate is ongoing
as to whether this is a causal factor or simply a risk
marker of more complex atrial cardiomyopathy.
Despite the wealth of data and mechanistic models,
the patterns and burden of AF that increase the risk
of cardioembolic stroke are not well understood.
The risk of stroke appears to be higher in permanent
or persistent AF than in paroxysmal AF.20 However, in
paroxysmal AF clinicians still lack an evidence-based
threshold for defining the absolute time burden of AF
where stroke risk is increased. Currently thresholds from
30 s to 6min, 5.5 h and up to 24h and longer are dis-
cussed in this context. The often substantial dissociation
of recorded AF episodes and embolic events further
challenge the hitherto understanding of stunned atrium
to mechanistically explain thrombus formation. In add-
ition to AF, other atrial arrhythmias, including frequent
supraventricular ectopic activity or subclinical atrial
tachycardia, are associated with an increased risk of
ischaemic stroke. Methods and length of heart rhythm
monitoring have been investigated intensely. Prolonged
electrocardiographic monitoring in patients who had a
stroke increases the detection rate of AF;21 however,
whether this translates into a reduction in the future
risk of stroke is not known. Implantable cardiac monitor
devices seem to provide the ultimate option for continued
monitoring for AF burden but efficacy and practicability
needs to be evaluated in combination with shorter and
less invasive monitoring strategies. Emerging wearable
consumer devices such as the smart watch and many
others yield great potential in the context of rhythm
monitoring. Further studies will show if such devices
may be applicable for clinical use for AF detection.
The concept of atrial myopathy is increasingly dis-
cussed as a pathophysiological concept of thrombus
formation resulting from complex atrial injury, wall
stress, local inflammation and fibrosis which leads to
atrial structural remodelling and increased thrombo-
genic potential. While atrial fibrosis has been addressed
as a major factor in this process, underlying mechan-
isms, clinical application and adequate measurement
tools or biomarker assessments are currently unclear.22
More work is needed to further characterise whether
AF or the underlying atrial cardiomyopathy is the
greatest contributor to stroke risk.
The CHA2DS2-VASc risk score is widely used and
guidelines are recommended for stroke risk prediction
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in patients with AF taking into account individual
patient characteristic comorbidities. While the cumu-
lative impact of confounding factors is well reflected in
the score, uncertainty exists as to the borderline risk
constellation of CHA2DS2-VASc score of one.
23
Incomplete data exist and need further validation as
to whether, and which, anticoagulation strategy can
be recommended at this low risk level.
Risk factor management in secondary prevention
Management of risk factors. As a general approach, after
the acute event of stroke, stroke patients should be recog-
nised as chronic patients, requiring chronic management
of stroke sequelae, risk factors and comorbidities to
improve the long-term outcome, to prevent recurrent
stroke events as well as cardiovascular events.
Cardiovascular events are common after stroke and are
the leading cause of death one year after an index stroke.24
The implementation of, and adherence to, risk factor
management after stroke is suboptimal with substantial
inequalities between countries in Europe. While struc-
tured and individualised rehabilitation concepts are
implemented in continued healthcare structures in
some countries, no such structured rehabilitation is
available in others. Stroke patients are often discharged
to primary care physicians without structured follow-up
of their cardiovascular condition. By contrast, a system-
atic, interdisciplinary approach would be needed com-
bining the expertise of cardiologists, stroke physicians
and other specialties for rehabilitation and management
of risk factors, cardiovascular complications and
comorbidities with continued monitoring and therapy
of patients after stroke (Figure 2). Ideally, cardiovascu-
lar diagnostic work-up led by cardiologists should be
started immediately at the index event hospitalisation
and should continue if needed after discharge to assess
the risk profiles and create a treatment plan that targets
prevention of both recurrent stroke and cardiovascular
events. Secondary prevention clinics staffed by specialty
trained nurses and, potentially, other health allied pro-
fessionals may be a tool to achieve better implementa-
tion of and adherence to secondary prevention
strategies (e.g. blood pressure and cholesterol reduction,
smoking cessation, anticoagulation in AF). Such collab-
oration between cardiologists, specialty nurses and
stroke physicians may be a key to achieving the
European Stroke Organisation’s (ESO) Action Plan
for Stroke, which specifically emphasises the importance
of secondary prevention and organised follow-up.25
Antiplatelet therapy. Antiplatelet therapy improves out-
come in patients with acute ischaemic stroke and tran-
sient ischemic attack (TIA), primarily by preventing
early recurrence of stroke.26 However, a risk of
secondary bleeding into infarcted tissues is greater for
larger infarcts and with early administration of antipla-
telet therapy. Combinations of dual antiplatelet ther-
apy or antiplatelet therapy with novel anticoagulation
(NOAC) therapy are subject to recent and ongoing
investigations.27 Different treatment regimens in patient
cohorts with overlapping risk profiles yield beneficial
results such as dual anti platelet therapy in patients
with cerebrovascular ischaemic event (POINT
(ClinicalTrials.gov identifier: NCT0099102))28 or anti-
platelet plus NOAC therapy in patients with cardiovas-
cular ischaemic disease (COMPASS (ClinicalTrials.gov
identifier: NCT01776424)).29 Further work is needed to
clarify the optimum treatment strategies in individual
risk- and comorbidity settings for easy clinical use.
Emerging data suggest different stroke subtypes may
respond differentially to antiplatelet agents, with ath-
erosclerotic stroke particularly benefitting from more
intensive antiplatelet therapy in the first few weeks
after the event,30 while small artery stroke had a
worse outcome with aspirin and clopidogrel than
aspirin alone, showing no reduction of ischaemic
stroke and an increased bleeding risk.31 Future trials
are warranted to focus on a precision medicine
approach to identify patients who have the greatest
likelihood of benefit and least likelihood of harm.
The Embolic Stroke of Unknown Source (ESUS) concept. In
contrast to extended monitoring for AF in patients with
cryptogenic stroke, the ESUS concept was recently
tested as an approach of minimal diagnostic workup
followed by rapid implementation of anticoagulation
therapy. Two major clinical trials (NAVIGATE-
ESUS (ClinicalTrials.gov identifier: NCT02313909),32
RESPECT-ESUS (ClinicalTrials.gov identifier:
NCT02239120))33 could, however, not show superiority
of this simplified diagnostic workup. This challenges
the underlying hypothesis that the majority of occur-
rences of ESUS would be caused by cardioembolic
events, and that limited diagnostic workup may be
sufficient for a one-size-fits-all-type of anticoagulation
therapy. Clearly, more thorough and individualised
cardiac diagnostic workup is needed to identify under-
lying pathology and appropriate therapy for those
patients. These results require further evaluation and
interpretation in the context of somehow contrasting
findings in the COMPASS trial (beneficial effect of
NOAC therapy in patients with ischaemic heart dis-
ease) but similar findings in the COMMANDER HF
trial (no benefit of NOAC in Heart failure patients).34
More evidence from ongoing trails (ATTICUS
(ClinicalTrials.gov identifier: NCT02427126),
ARCADIA (ClinicalTrials.gov identifier:
NCT03192215)) is awaited to inform the ongoing dis-
cussion on the applicability of the ESUS concept.
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Occlusion therapies for persistent foramen ovale and
left atrial appendage
For patients with AF and a high risk of ischaemic
stroke who have contraindications for long-term antic-
oagulation, other approaches for stroke prevention
need to be explored. Occlusion of a patent foramen
ovale has been shown in recent trials to yield beneficial
results in patients with cryptogenic stroke yet optimum
patient selection for this novel invasive therapy and
timing is still a matter of ongoing debate. Left atrial
appendage closure has been suggested as a potential
therapeutic option. However, more data are needed to
establish the clinical efficacy and safety of this approach
Admission to stroke centre / Stroke unit with suspected  stroke
Emergency measures and immediate initiation of acute stroke treatment 
Stroke rehabilitation and long-term post stroke care 
Subacute therapy / stroke unit monitoring
Stroke physician
Acute diagnostics
• Functional deficits 
• Clinical presentation
• Lesion localisation, 
• Imaging for location, aetiology 
and size of cerebral injury
Acute therapy (in collaboration with interventional specialists)
Individualised rehabilitation program
• To maximise physical and 
neuro-cognitive recovery 
• Collaboration with 
neurorehabilitation specialists
Cardiologist
Acute diagnostic workup 
• Cardiac history and comorbidities
• Cardiac imaging - stroke aetiology  
and undetected (causal?) 
cardiac comorbidities 
Neurological complications
• Seizures, cramps, 
• Central control of vital functions 
• Cognitive failure
Oversee subsequent diagnostic workup 
and medical management 
Cardiovascular complications
• (supra-) ventricular arrhythmias 
• Blood pressure emergencies
• Cardiac function 
(neurogenic myocardial injury)  
• Diagnostic and treatment 
of prevalent cv comorbidities
of acute cv comorbidities: 
(e.g. endocarditis, 
cardiac decompensations)
Early cardiovascular risk assessment
• Risk profile assessment 
and treatment plan
Continued monitoring and therapy 
for secondary prevention
• Definite treatment of cv comorbidities 
• Management of cv risk factors
Figure 2. Interdisciplinary delivery of stroke care. While inpatient management is overseen by stroke physicians, early and continued
support should be provided by cardiology consultation as a consistent component of an integrated care model through all phases of
stroke care for acute and subacute therapies, diagnostic workup, handling of cardiovascular complications of stroke and secondary
prevention. Follow-up after discharge by both specialties is recommended, with support from a cv secondary prevention clinic to
ensure implementation of and adherence to secondary prevention strategies. Secondary prevention can be provided by primary care,
if available, or a specialty nurse-directed clinica for risk factor management can be envisioned for this purpose.
cv: cardiovascular.
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(current ESC guideline class of recommendation IIb,
level of evidence B).35 Two larger trials of left atrial
appendage closure in patients with high ischaemic and
very high bleeding risk are currently ongoing
(CLOSURE-AF (ClinicalTrials.gov identifier:
NCT03463317), STROKECLOSE (ClinicalTrials.gov
identifier: NCT02830152)).
Acute stroke
Percutaneous thrombectomy
Percutaneous thrombectomy is a relatively new treat-
ment for acute stroke. Data from five trials of second-
generation neurothrombectomy devices in 1287 patients
with stroke due to large vessel occlusions showed that
this therapy significantly reduced disability at 90 days.36
Not addressed in these trials were patients with poster-
ior circulation occlusion, substantial disability (modi-
fied Rankin score 2), and large baseline infarcts.
Uncertainty remains about a number of specific aspects
of this novel therapy such as the adequate andmaximum
time windows, optimum combination with thrombolytic
therapy, and accessible vascular territories.
Mechanical thrombectomy therapy is in a very early
stage of clinical implementation, and further studies
and clinical experience are warranted to explore the
full potential of catheter intervention for brain ischae-
mia. The advances with mechanical thrombectomy may
resemble the evolution in percutaneous coronary inter-
vention, from balloon angioplasty in the 1980s to bare
metal stents in the 1990s and drug-eluting stents in
the 2000s.
Treatment of stroke-induced cardiovascular
complications
Cardiovascular complications are common in the early
post-stroke period and are a major reason to explain
the benefit of stroke unit care in the subacute phase
after stroke. These events may represent a stroke-
specific pattern of a neurogenic heart syndrome where
severe imbalances in sympathetic and parasympathetic
activity and peripheral reflex circuits lead to cardio-
vascular dysregulation such as hypertensive crises,
coronary vasospasm, supraventricular or ventricular
arrhythmias, contraction band necrosis or takotsubo-
like cardiomyopathy (Figure 1).37 Cardiologist expert-
ise should be present in stroke unit settings as a
consistent component of an integrated care model to
address the multiple cardiovascular aspects of post-
stroke care. These may include arrhythmia manage-
ment, blood pressure control (both hypertensive crisis
and hypotension), elevated cardiac troponin (which are
often not due to culprit coronary lesions), endocarditis
and general management of cardiovascular comorbid-
ities (heart failure,38 valvular disease, chronic ischaemic
coronary artery disease).4 The management of these
cardiovascular conditions often extends beyond the
acute phase and should be continued in chronic care
settings (see also next chapter). Collaboration of med-
ical societies across clinical specialties is needed to
create consistent guidelines for the management of car-
diovascular conditions in the setting of acute stroke.
Integrated healthcare systems and networks
In ischaemic stroke, time dependency of treatment ini-
tiation is a crucial factor to determine treatment efficacy
and outcome. Systems of care must be designed to min-
imise delays in assessment and initiation of treatment.
New imaging modalities may be one method that can
promote efficiencies in the system and reduce treatment
delays.39
Patient access to stroke care varies widely among
countries in the European Union (EU), and even
within regions of a single country, hence major inequal-
ities exist in availabilities of stroke unit care, intraven-
ous thrombolysis and endovascular therapy. Stroke
unit numbers range from 1.5–5.8 stroke units per
1000 annual incidents, estimates of mean annual num-
bers for intravenous thrombolysis ranged from 72–205
per 1000 annual incidents and for endovascular treat-
ments ranged from 19–56 per 1000 annual incidents.40
Interdisciplinary consensus guidelines are warranted to
recommend a minimum standard of care that should be
provided to all patients, regardless of country. Such
recommendations may help minimise the disparities in
stroke care that currently exist in the EU, and they
would be a helpful resource for professional organiza-
tions who are working with health authorities to
improve timely patient access to stroke centres. The
European Society of Cardiology is committed to part-
nering with the ESO, European Society of Minimal
Invasive Therapy (ESMINT), European Society of
Vascular Surgery (ESVS) as well as with national
societies, and local health authorities to develop these
minimum standards and ensure their effective imple-
mentation across the EU.
Conclusion
Many advances in stroke care have been achieved,
resulting in better patient outcomes and decreased mor-
tality. Interdisciplinary concepts of modern stroke care
call for consistent and structured involvement of cardio-
vascular expertise in diagnostics, acute and subacute
therapy, primary and secondary prevention and follow-
up measures in stroke. Many gaps in evidence remain
and have been identified as targets for further initiatives.
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These gaps present challenges as well as opportunities to
clinicians, researchers, industry, and professional organ-
izations to improve stroke care and reduce its associated
burden. Cardiologists and stroke physicians should com-
municate closely and in collaboration with industry to
further develop the tools, resources and treatments that
would be useful for improving efficiency and reducing
the time to treatment. Such communication will help to
drive innovations in the identified areas of greatest need.
The ESC is determined to promote interdisciplinary col-
laboration and to pursue integrated care strategies by
driving activities of clinical education and scientific
exchange, encouraging research, and fostering guideline
development towards comprehensive concepts of stroke
prevention and treatment.
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